S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:NMTR

9 Meters Biopharma Stock Forecast, Price & News

$0.72
-0.03 (-4.00%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.72
$0.77
50-Day Range
$0.72
$1.09
52-Week Range
$0.72
$2.26
Volume
746,328 shs
Average Volume
1.33 million shs
Market Capitalization
$184.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.23
30 days | 90 days | 365 days | Advanced Chart
Receive NMTR News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.


9 Meters Biopharma logo

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Headlines

Raleigh public company adds former Biogen exec to C-suite
January 21, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.16 per share

Profitability

Net Income
$-61.50 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
248,509,000
Market Cap
$184.16 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/28/2022
Next Earnings (Estimated)
3/28/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

446th out of 1,417 stocks

Pharmaceutical Preparations Industry

201st out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 9 Meters Biopharma stock.
View analyst ratings for 9 Meters Biopharma
or view top-rated stocks.

When is 9 Meters Biopharma's next earnings date?

9 Meters Biopharma is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for 9 Meters Biopharma
.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.
View 9 Meters Biopharma's earnings history
.

What price target have analysts set for NMTR?

6 analysts have issued 1-year target prices for 9 Meters Biopharma's stock. Their forecasts range from $3.00 to $6.00. On average, they expect 9 Meters Biopharma's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 594.2% from the stock's current price.
View analysts' price targets for 9 Meters Biopharma
or view top-rated stocks among Wall Street analysts.

Who are 9 Meters Biopharma's key executives?

9 Meters Biopharma's management team includes the following people:
  • John Temperato, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Sireesh Appajosyula, SVP-Corporate Development & Operations
  • Bethany L. Sensenig, Chief Financial & Accounting Officer
  • Patrick H. Griffin, Chief Medical Officer
  • Sarah Liu, Chief Commercial Officer

What other stocks do shareholders of 9 Meters Biopharma own?

What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

Who are 9 Meters Biopharma's major shareholders?

9 Meters Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include J.W. Cole Advisors Inc. (0.02%). Company insiders that own 9 Meters Biopharma stock include Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino.
View institutional ownership trends for 9 Meters Biopharma
.

Which major investors are buying 9 Meters Biopharma stock?

NMTR stock was bought by a variety of institutional investors in the last quarter, including J.W. Cole Advisors Inc.. Company insiders that have bought 9 Meters Biopharma stock in the last two years include Edward J Sitar, John Temperato, Mark A Sirgo, and Michael T Constantino.
View insider buying and selling activity for 9 Meters Biopharma
or or view top insider-buying stocks.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $0.72.

How much money does 9 Meters Biopharma make?

9 Meters Biopharma has a market capitalization of $184.16 million.

How many employees does 9 Meters Biopharma have?

9 Meters Biopharma employs 12 workers across the globe.

What is 9 Meters Biopharma's official website?

The official website for 9 Meters Biopharma is www.9meters.com.

Where are 9 Meters Biopharma's headquarters?

9 Meters Biopharma is headquartered at 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at (919) 275-1933 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.